Cargando…
Urine-sample-derived human induced pluripotent stem cells as a model to study PCSK9-mediated autosomal dominant hypercholesterolemia
Proprotein convertase subtilisin kexin type 9 (PCSK9) is a critical modulator of cholesterol homeostasis. Whereas PCSK9 gain-of-function (GOF) mutations are associated with autosomal dominant hypercholesterolemia (ADH) and premature atherosclerosis, PCSK9 loss-of-function (LOF) mutations have a card...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Company of Biologists
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4728336/ https://www.ncbi.nlm.nih.gov/pubmed/26586530 http://dx.doi.org/10.1242/dmm.022277 |
_version_ | 1782412090227556352 |
---|---|
author | Si-Tayeb, Karim Idriss, Salam Champon, Benoite Caillaud, Amandine Pichelin, Matthieu Arnaud, Lucie Lemarchand, Patricia Le May, Cédric Zibara, Kazem Cariou, Bertrand |
author_facet | Si-Tayeb, Karim Idriss, Salam Champon, Benoite Caillaud, Amandine Pichelin, Matthieu Arnaud, Lucie Lemarchand, Patricia Le May, Cédric Zibara, Kazem Cariou, Bertrand |
author_sort | Si-Tayeb, Karim |
collection | PubMed |
description | Proprotein convertase subtilisin kexin type 9 (PCSK9) is a critical modulator of cholesterol homeostasis. Whereas PCSK9 gain-of-function (GOF) mutations are associated with autosomal dominant hypercholesterolemia (ADH) and premature atherosclerosis, PCSK9 loss-of-function (LOF) mutations have a cardio-protective effect and in some cases can lead to familial hypobetalipoproteinemia (FHBL). However, limitations of the currently available cellular models preclude deciphering the consequences of PCSK9 mutation further. We aimed to validate urine-sample-derived human induced pluripotent stem cells (UhiPSCs) as an appropriate tool to model PCSK9-mediated ADH and FHBL. To achieve our goal, urine-sample-derived somatic cells were reprogrammed into hiPSCs by using episomal vectors. UhiPSC were efficiently differentiated into hepatocyte-like cells (HLCs). Compared to control cells, cells originally derived from an individual with ADH (HLC-S127R) secreted less PCSK9 in the media (−38.5%; P=0.038) and had a 71% decrease (P<0.001) of low-density lipoprotein (LDL) uptake, whereas cells originally derived from an individual with FHBL (HLC-R104C/V114A) displayed a strong decrease in PCSK9 secretion (−89.7%; P<0.001) and had a 106% increase (P=0.0104) of LDL uptake. Pravastatin treatment significantly enhanced LDL receptor (LDLR) and PCSK9 mRNA gene expression, as well as PCSK9 secretion and LDL uptake in both control and S127R HLCs. Pravastatin treatment of multiple clones led to an average increase of LDL uptake of 2.19±0.77-fold in HLC-S127R compared to 1.38±0.49 fold in control HLCs (P<0.01), in line with the good response to statin treatment of individuals carrying the S127R mutation (mean LDL cholesterol reduction=60.4%, n=5). In conclusion, urine samples provide an attractive and convenient source of somatic cells for reprogramming and hepatocyte differentiation, but also a powerful tool to further decipher PCSK9 mutations and function. |
format | Online Article Text |
id | pubmed-4728336 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | The Company of Biologists |
record_format | MEDLINE/PubMed |
spelling | pubmed-47283362016-02-01 Urine-sample-derived human induced pluripotent stem cells as a model to study PCSK9-mediated autosomal dominant hypercholesterolemia Si-Tayeb, Karim Idriss, Salam Champon, Benoite Caillaud, Amandine Pichelin, Matthieu Arnaud, Lucie Lemarchand, Patricia Le May, Cédric Zibara, Kazem Cariou, Bertrand Dis Model Mech Resource Article Proprotein convertase subtilisin kexin type 9 (PCSK9) is a critical modulator of cholesterol homeostasis. Whereas PCSK9 gain-of-function (GOF) mutations are associated with autosomal dominant hypercholesterolemia (ADH) and premature atherosclerosis, PCSK9 loss-of-function (LOF) mutations have a cardio-protective effect and in some cases can lead to familial hypobetalipoproteinemia (FHBL). However, limitations of the currently available cellular models preclude deciphering the consequences of PCSK9 mutation further. We aimed to validate urine-sample-derived human induced pluripotent stem cells (UhiPSCs) as an appropriate tool to model PCSK9-mediated ADH and FHBL. To achieve our goal, urine-sample-derived somatic cells were reprogrammed into hiPSCs by using episomal vectors. UhiPSC were efficiently differentiated into hepatocyte-like cells (HLCs). Compared to control cells, cells originally derived from an individual with ADH (HLC-S127R) secreted less PCSK9 in the media (−38.5%; P=0.038) and had a 71% decrease (P<0.001) of low-density lipoprotein (LDL) uptake, whereas cells originally derived from an individual with FHBL (HLC-R104C/V114A) displayed a strong decrease in PCSK9 secretion (−89.7%; P<0.001) and had a 106% increase (P=0.0104) of LDL uptake. Pravastatin treatment significantly enhanced LDL receptor (LDLR) and PCSK9 mRNA gene expression, as well as PCSK9 secretion and LDL uptake in both control and S127R HLCs. Pravastatin treatment of multiple clones led to an average increase of LDL uptake of 2.19±0.77-fold in HLC-S127R compared to 1.38±0.49 fold in control HLCs (P<0.01), in line with the good response to statin treatment of individuals carrying the S127R mutation (mean LDL cholesterol reduction=60.4%, n=5). In conclusion, urine samples provide an attractive and convenient source of somatic cells for reprogramming and hepatocyte differentiation, but also a powerful tool to further decipher PCSK9 mutations and function. The Company of Biologists 2016-01-01 /pmc/articles/PMC4728336/ /pubmed/26586530 http://dx.doi.org/10.1242/dmm.022277 Text en © 2016. Published by The Company of Biologists Ltd http://creativecommons.org/licenses/by/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed. |
spellingShingle | Resource Article Si-Tayeb, Karim Idriss, Salam Champon, Benoite Caillaud, Amandine Pichelin, Matthieu Arnaud, Lucie Lemarchand, Patricia Le May, Cédric Zibara, Kazem Cariou, Bertrand Urine-sample-derived human induced pluripotent stem cells as a model to study PCSK9-mediated autosomal dominant hypercholesterolemia |
title | Urine-sample-derived human induced pluripotent stem cells as a model to study PCSK9-mediated autosomal dominant hypercholesterolemia |
title_full | Urine-sample-derived human induced pluripotent stem cells as a model to study PCSK9-mediated autosomal dominant hypercholesterolemia |
title_fullStr | Urine-sample-derived human induced pluripotent stem cells as a model to study PCSK9-mediated autosomal dominant hypercholesterolemia |
title_full_unstemmed | Urine-sample-derived human induced pluripotent stem cells as a model to study PCSK9-mediated autosomal dominant hypercholesterolemia |
title_short | Urine-sample-derived human induced pluripotent stem cells as a model to study PCSK9-mediated autosomal dominant hypercholesterolemia |
title_sort | urine-sample-derived human induced pluripotent stem cells as a model to study pcsk9-mediated autosomal dominant hypercholesterolemia |
topic | Resource Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4728336/ https://www.ncbi.nlm.nih.gov/pubmed/26586530 http://dx.doi.org/10.1242/dmm.022277 |
work_keys_str_mv | AT sitayebkarim urinesamplederivedhumaninducedpluripotentstemcellsasamodeltostudypcsk9mediatedautosomaldominanthypercholesterolemia AT idrisssalam urinesamplederivedhumaninducedpluripotentstemcellsasamodeltostudypcsk9mediatedautosomaldominanthypercholesterolemia AT champonbenoite urinesamplederivedhumaninducedpluripotentstemcellsasamodeltostudypcsk9mediatedautosomaldominanthypercholesterolemia AT caillaudamandine urinesamplederivedhumaninducedpluripotentstemcellsasamodeltostudypcsk9mediatedautosomaldominanthypercholesterolemia AT pichelinmatthieu urinesamplederivedhumaninducedpluripotentstemcellsasamodeltostudypcsk9mediatedautosomaldominanthypercholesterolemia AT arnaudlucie urinesamplederivedhumaninducedpluripotentstemcellsasamodeltostudypcsk9mediatedautosomaldominanthypercholesterolemia AT lemarchandpatricia urinesamplederivedhumaninducedpluripotentstemcellsasamodeltostudypcsk9mediatedautosomaldominanthypercholesterolemia AT lemaycedric urinesamplederivedhumaninducedpluripotentstemcellsasamodeltostudypcsk9mediatedautosomaldominanthypercholesterolemia AT zibarakazem urinesamplederivedhumaninducedpluripotentstemcellsasamodeltostudypcsk9mediatedautosomaldominanthypercholesterolemia AT carioubertrand urinesamplederivedhumaninducedpluripotentstemcellsasamodeltostudypcsk9mediatedautosomaldominanthypercholesterolemia |